Interrogating the Gut-Brain Axis in the Context of Inflammatory Bowel Disease: A Translational Approach.

Abstract:

:This review examines preclinical and clinical studies relevant to our understanding of how the bidirectional gut-brain axis influences the natural history of inflammatory bowel disease. Preclinical studies provide proof of concept that preexisting behavioral illness, such as depression, results in increased susceptibility to inflammatory stimuli and that commonly used classes of antidepressants protect against this vulnerability. However, clinical studies suggesting behavioral illness as a risk factor for IBD and a protective role for antidepressants have relied primarily on symptom-reporting rather than objective measurements of inflammation. In terms of gut-to-brain signaling, there is emerging evidence from preclinical and clinical observation that intestinal inflammation alters brain functions, including the induction of mood disorders, alteration of circadian rhythm both centrally and peripherally, and changes in appetitive behaviors. Furthermore, preclinical studies suggest that effective treatment of intestinal inflammation improves associated behavioral impairment. Taken together, the findings of this review encourage a holistic approach to the management of patients with IBD, accommodating lifestyle issues that include the avoidance of sleep deprivation, optimized nutrition, and the monitoring and appropriate management of behavioral disorders. The review also acknowledges the need for better-designed clinical studies evaluating the impact of behavioral disorders and their treatments on the natural history of IBD, utilizing hard end points to assess changes in the inflammatory process as opposed to reliance on symptom-based assessments. The findings of the review also encourage a better understanding of changes in brain function and circadian rhythm induced by intestinal inflammation.

journal_name

Inflamm Bowel Dis

authors

Collins SM

doi

10.1093/ibd/izaa004

subject

Has Abstract

pub_date

2020-03-04 00:00:00

pages

493-501

issue

4

eissn

1078-0998

issn

1536-4844

pii

5714219

journal_volume

26

pub_type

杂志文章
  • Validation of a Simple 0 to 10 Numerical Score (IBD-10) of Patient-reported Inflammatory Bowel Disease Activity for Routine Clinical Use.

    abstract:BACKGROUND:Various physician- and patient-reported instruments exist for quantification of disease activity in inflammatory bowel diseases (IBD) but none are widely used in routine clinical practice. A simple patient-reported outcome measure might help inform clinical decision making. We evaluated a patient-reported 0 ...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1097/MIB.0000000000000803

    authors: Subramanian S,Asher R,Weston W,Rimmer M,McConville A,Malin A,Jackson R,Collins P,Probert C,Dibb M,Rhodes JM

    更新日期:2016-08-01 00:00:00

  • Crohn's is not a 6-week disease: lifelong management of mild to moderate Crohn's disease.

    abstract::Crohn's disease is an idiopathic, chronic inflammatory disorder of the digestive tract with heterogeneous clinical presentations. Crohn's is currently not a curable disease, and patients are faced with a lifetime of recurrent disease flare-ups and remissions. Management strategies for Crohn's must therefore be targete...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章,评审

    doi:10.1097/00054725-200407002-00002

    authors: Lichtenstein GR,Hanauer SB,Kane SV,Present DH

    更新日期:2004-07-01 00:00:00

  • Mechanisms that mediate the development of fibrosis in patients with Crohn's disease.

    abstract::Crohn's disease is complicated by the development of fibrosis and stricture in approximately 30% to 50% of patients over time. The pathogenesis of fibrostenotic disease is multifactorial involving the activation of mesenchymal cells by cytokines, growth factors, and other mediators released by immune cells, epithelial...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章,评审

    doi:10.1097/MIB.0000000000000043

    authors: Li C,Kuemmerle JF

    更新日期:2014-07-01 00:00:00

  • Genetic and environmental context determines the course of colitis developing in IL-10-deficient mice.

    abstract::This review summarizes how interleukin-10 (IL-10)-deficient mice have permitted new insight into the complex interaction between genes and environment underlying pathogenesis of inflammatory bowel disease (IBD). The C57BL/6J strain develops only mild typhlocolitis in response to IL-10 deficiency. In contrast, C3H/HeJB...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章,评审

    doi:10.1097/00054725-200209000-00006

    authors: Mähler M,Leiter EH

    更新日期:2002-09-01 00:00:00

  • Changes in the Abundance of Faecalibacterium prausnitzii Phylogroups I and II in the Intestinal Mucosa of Inflammatory Bowel Disease and Patients with Colorectal Cancer.

    abstract:BACKGROUND:Faecalibacterium prausnitzii comprises 2 phylogroups, whose abundance in healthy and diseased gut and in conjunction with Escherichia coli has not yet been studied. This work aims to determine the contribution of F. prausnitzii phylogroups I and II in intestinal disease and to assess their potential diagnost...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1097/MIB.0000000000000590

    authors: Lopez-Siles M,Martinez-Medina M,Surís-Valls R,Aldeguer X,Sabat-Mir M,Duncan SH,Flint HJ,Garcia-Gil LJ

    更新日期:2016-01-01 00:00:00

  • Interleukin 10-deficient mice exhibit defective colonic Muc2 synthesis before and after induction of colitis by commensal bacteria.

    abstract::Germ-free (GF) interleukin 10-deficient (IL-10) mice develop chronic colitis after colonization by normal enteric bacteria. Muc2 is the major structural component of the protective colonic mucus. Our aim was to determine whether primary or induced aberrations in Muc2 synthesis occur in GF IL-10 mice that develop colit...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1097/00054725-200411000-00016

    authors: Schwerbrock NM,Makkink MK,van der Sluis M,Büller HA,Einerhand AW,Sartor RB,Dekker J

    更新日期:2004-11-01 00:00:00

  • Childhood Maltreatment Is Associated with Ulcerative Colitis but Not Crohn's Disease: Findings from a Population-based Study.

    abstract:BACKGROUND:Previous research suggests a link between childhood adversities and inflammatory bowel disease (IBD); however, study limitations prevent generalization of findings. To address this, the current study uses a Canadian population-based sample to investigate the relationship between 3 childhood adversities and 2...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1097/MIB.0000000000000551

    authors: Fuller-Thomson E,West KJ,Sulman J,Baird SL

    更新日期:2015-11-01 00:00:00

  • 5-Aminosalicylates and renal function in inflammatory bowel disease: a systematic review.

    abstract::Nephrotoxicity has been described in some patients with inflammatory bowel disease (IBD) treated with 5-aminosalicylic acid (5-ASA). Studies with 5-ASA treatment in which serum creatinine or creatinine clearance was measured regularly show that nephrotoxicity is exceptional (mean rate of only 0.26% per patient-year). ...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章,评审

    doi:10.1002/ibd.20099

    authors: Gisbert JP,González-Lama Y,Maté J

    更新日期:2007-05-01 00:00:00

  • Dosage adjustment during long-term adalimumab treatment for Crohn's disease: clinical efficacy and pharmacoeconomics.

    abstract:BACKGROUND:Data from CHARM, a 56-week, randomized controlled trial of adalimumab for patients with moderately to severely active Crohn's disease (CD), were used to evaluate outcomes of adalimumab dosage adjustment. METHODS:Patients randomized to blinded adalimumab 40 mg every other week (EOW) in CHARM were the focus o...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章,随机对照试验

    doi:10.1002/ibd.21328

    authors: Sandborn WJ,Colombel JF,Schreiber S,Plevy SE,Pollack PF,Robinson AM,Chao J,Mulani P

    更新日期:2011-01-01 00:00:00

  • Etiology of pouchitis.

    abstract::Restorative proctocolectomy with ileal-pouch anal anastomosis (RPC) is the operation of choice for ulcerative colitis (UC) patients requiring surgery. It is also used for patients with familial adenomatous polyposis (FAP). Pouchitis accounts for 10% of pouch failures. It is an idiopathic inflammatory condition that ma...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章,评审

    doi:10.1002/ibd.21911

    authors: Landy J,Al-Hassi HO,McLaughlin SD,Knight SC,Ciclitira PJ,Nicholls RJ,Clark SK,Hart AL

    更新日期:2012-06-01 00:00:00

  • Endoscopic Balloon Dilation Size and Avoidance of Surgery in Stricturing Crohn's Disease.

    abstract:BACKGROUND:Endoscopic balloon dilation (EBD) is an effective method for treating stricture-related obstruction in Crohn's disease. We aimed to identify factors predictive of successful avoidance of surgery, including endoscopic features, in patients undergoing balloon dilation. METHODS:We performed a retrospective rev...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1097/MIB.0000000000001181

    authors: Reutemann BA,Turkeltaub JA,Al-Hawary M,Waljee AK,Higgins PDR,Stidham RW

    更新日期:2017-10-01 00:00:00

  • Safety and tolerability of human placenta-derived cells (PDA001) in treatment-resistant crohn's disease: a phase 1 study.

    abstract:BACKGROUND:The clinical utility of cellular therapies is being investigated in a broad range of therapeutic areas. This phase 1 study represents the first exploration of PDA001, a preparation of cells cultured from human placental tissue, in subjects with Crohn's disease. METHODS:Twelve subjects with active, moderate-...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章,多中心研究

    doi:10.1097/MIB.0b013e31827f27df

    authors: Mayer L,Pandak WM,Melmed GY,Hanauer SB,Johnson K,Payne D,Faleck H,Hariri RJ,Fischkoff SA

    更新日期:2013-03-01 00:00:00

  • Analysis of current treatments used in clinical practice in a pediatric summer camp population for children with inflammatory bowel disease.

    abstract:BACKGROUND:Many treatment options exist for children with inflammatory bowel disease (IBD), yet the lack of clinical guidelines for management has lead to great variation in care. The purpose of this project was to evaluate current treatment modalities in children from the Northeast US who applied to the 2010 session o...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1002/ibd.22837

    authors: Rosen D,Kathy-Hoffstadter-Thal,Bao R,Tomaino J,Ceballos C,Russell GJ,Benkov KJ

    更新日期:2012-10-01 00:00:00

  • VSL#3 Probiotic Stimulates T-cell Protein Tyrosine Phosphatase-mediated Recovery of IFN-γ-induced Intestinal Epithelial Barrier Defects.

    abstract:BACKGROUND:VSL#3 is a probiotic compound that has been used in the treatment of inflammatory bowel disease. T-cell protein tyrosine phosphatase (TCPTP) is the protein product of the inflammatory bowel disease candidate gene, PTPN2, and we have previously shown that it protects epithelial barrier function. The aim of th...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1097/MIB.0000000000000954

    authors: Krishnan M,Penrose HM,Shah NN,Marchelletta RR,McCole DF

    更新日期:2016-12-01 00:00:00

  • Healing of intestinal inflammation by IL-22.

    abstract::An interleukin (IL)-10 family cytokine, IL-22 is characterized by several unique biological properties, including 1) the target restricted to innate cells; 2) the distinct expression pattern between large and small intestines; 3) alteration of the cellular source depending on several factors; 4) the dual abilities to ...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章,评审

    doi:10.1002/ibd.22929

    authors: Mizoguchi A

    更新日期:2012-09-01 00:00:00

  • Direct comparison of two different mesalamine formulations for the induction of remission in patients with ulcerative colitis: a double-blind, randomized study.

    abstract:BACKGROUND:Mesalamine is the first-line drug for the treatment of ulcerative colitis (UC). We directly compared the efficacy and safety of two mesalamine formulations for the induction of remission in patients with UC. METHODS:In a multicenter, double-blind, randomized study, 229 patients with mild-to-moderate active ...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1002/ibd.21193

    authors: Ito H,Iida M,Matsumoto T,Suzuki Y,Sasaki H,Yoshida T,Takano Y,Hibi T

    更新日期:2010-09-01 00:00:00

  • Lack of Vitamin D Receptor Leads to Hyperfunction of Claudin-2 in Intestinal Inflammatory Responses.

    abstract:Background:Vitamin D3 and vitamin D receptor (VDR) are involved in the pathogenesis of inflammatory bowel disease (IBD) and bacterial infection. Claudin-2 is a junction protein that mediates paracellular water transport in epithelia. Elevation of Claudin-2 is associated with active IBD. However, VDR involved in epithel...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1093/ibd/izy292

    authors: Zhang YG,Lu R,Xia Y,Zhou D,Petrof E,Claud EC,Sun J

    更新日期:2019-01-01 00:00:00

  • Aneuploidy-associated gene expression signatures characterize malignant transformation in ulcerative colitis.

    abstract:BACKGROUND:Malignant transformation in ulcerative colitis (UC) is associated with pronounced chromosomal instability, reflected by aneuploidy. Although aneuploidy can precede primary cancer diagnosis in UC for more than a decade, little is known of its cellular consequences. METHODS:Whole-genome gene expression analys...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1097/MIB.0b013e31827eeaa4

    authors: Gerling M,Nousiainen K,Hautaniemi S,Krüger S,Fritzsche B,Homann N,Bruch HP,Auer G,Roblick UJ,Ried T,Habermann JK

    更新日期:2013-03-01 00:00:00

  • Incidence, Clinical Characteristics, and Management of Psoriasis Induced by Anti-TNF Therapy in Patients with Inflammatory Bowel Disease: A Nationwide Cohort Study.

    abstract:BACKGROUND:Psoriasis induced by anti-tumor necrosis factor-α (TNF) therapy has been described as a paradoxical side effect. AIM:To determine the incidence, clinical characteristics, and management of psoriasis induced by anti-TNF therapy in a large nationwide cohort of inflammatory bowel disease patients. METHODS:Pat...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章,多中心研究

    doi:10.1097/MIB.0000000000000757

    authors: Guerra I,Pérez-Jeldres T,Iborra M,Algaba A,Monfort D,Calvet X,Chaparro M,Mañosa M,Hinojosa E,Minguez M,Ortiz de Zarate J,Márquez L,Prieto V,García-Sánchez V,Guardiola J,Rodriguez GE,Martín-Arranz MD,García-Tercero I,S

    更新日期:2016-04-01 00:00:00

  • Therapeutic effects of a new lymphocyte homing reagent FTY720 in interleukin-10 gene-deficient mice with colitis.

    abstract:BACKGROUND:FTY720 is a novel reagent that possesses potent immunosuppressive activity. The immunosuppression induced by FTY720 is mediated by completely different mechanisms from those of conventional immunosuppressants, that is, by altering the tissue distribution of lymphocytes rather than inhibiting activation. In t...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1097/00054725-200405000-00002

    authors: Mizushima T,Ito T,Kishi D,Kai Y,Tamagawa H,Nezu R,Kiyono H,Matsuda H

    更新日期:2004-05-01 00:00:00

  • Endocytosis of Intestinal Tight Junction Proteins: In Time and Space.

    abstract::Eukaryotic cells take up macromolecules and particles from the surrounding milieu and also internalize membrane proteins via a precise process of endocytosis. The role of endocytosis in diverse physiological processes such as cell adhesion, cell signaling, tissue remodeling, and healing is well recognized. The epithel...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1093/ibd/izaa141

    authors: Nighot P,Ma T

    更新日期:2021-01-19 00:00:00

  • Comparative Evaluation of Conventional Stool Testing and Multiplex Molecular Panel in Outpatients With Relapse of Inflammatory Bowel Disease.

    abstract:BACKGROUND:Differentiating between enteric infection and relapse of inflammatory bowel disease (IBD) is a common clinical challenge. Few studies have evaluated the impact of multiplex gastrointestinal polymerase chain reaction (GI PCR) pathogen panels on clinical practice compared to stool culture. Our aim was to compa...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1093/ibd/izaa336

    authors: Hong S,Zaki TA,Main M,Hine AM,Chang S,Hudesman D,Axelrad JE

    更新日期:2021-01-02 00:00:00

  • Influence of sulfasalazine and olsalamine on colonic epithelial cell folate content in patients with ulcerative colitis.

    abstract::: Inflammatory bowel disease is associated with a reduction in serum and red blood cell folate levels that may contribute to colonic carcinogenesis. Sulfasalazine may exacerbate such deficiencies. Indirect evidence suggests that folate supplements reduce the risk of colonic neoplasia in those using this agent, althoug...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:

    authors: Meenan J,Oʼhallinan E,Scott J,Weir DG

    更新日期:1996-10-01 00:00:00

  • Phenotype classification in IBD: Is there an impact on therapy?

    abstract::This review summarizes the current phenotypic classifications of inflammatory bowel disease (IBD) and outlines their implications for diagnosis, therapy, prognosis, clinical trial design, and genotype-phenotype correlations. ...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1002/ibd.20232

    authors: Walfish A,Sachar D

    更新日期:2007-12-01 00:00:00

  • Treatment patterns, complications, and disease relapse in a real-world population of patients with moderate-to-severe ulcerative colitis initiating immunomodulator therapy.

    abstract:BACKGROUND:Immunomodulator (IM) treatments in ulcerative colitis (UC) are not curative and carry increased risk of complications, sometimes leading to therapy changes, reduced treatment benefits, and eventual relapse. We assessed patterns of IM utilization and therapy changes, complications, and disease relapse in a re...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1097/MIB.0000000000000089

    authors: Loftus EV Jr,Davis KL,Wang CC,Dastani H,Luo A

    更新日期:2014-08-01 00:00:00

  • Patient-reported Anxiety: A Possible Predictor of Pediatric Inflammatory Bowel Disease Health Care Use.

    abstract:BACKGROUND:Anxiety is linked with adverse health-related outcomes and increased health-seeking behaviors among patients with chronic illness. Yet, this relationship has received little attention in pediatric inflammatory bowel disease. The aim of this study was to examine whether anxiety symptoms predicted youth at inc...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1097/MIB.0000000000000864

    authors: Reigada LC,Satpute A,Hoogendoorn CJ,Cohen BH,Lai J,Bao R,Dubinsky MC,Benkov KJ

    更新日期:2016-09-01 00:00:00

  • AVX-470: a novel oral anti-TNF antibody with therapeutic potential in inflammatory bowel disease.

    abstract:BACKGROUND:Inflammatory bowel disease (IBD) is a chronic inflammatory disease of the gastrointestinal tract, which is currently treated with injected monoclonal antibodies specific for tumor necrosis factor (TNF). We developed and characterized AVX-470, a novel polyclonal antibody specific for human TNF. We evaluated t...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1097/MIB.0b013e3182a11958

    authors: Bhol KC,Tracey DE,Lemos BR,Lyng GD,Erlich EC,Keane DM,Quesenberry MS,Holdorf AD,Schlehuber LD,Clark SA,Fox BS

    更新日期:2013-10-01 00:00:00

  • Poor Sleep Quality in Crohn's Disease Is Associated With Disease Activity and Risk for Hospitalization or Surgery.

    abstract:BACKGROUND AND AIMS:Poor sleep quality in Crohn's disease (CD) is associated with histologic activity and clinical relapse. We sought to characterize sleep dysfunction and determine the effect of poor sleep quality on risk for hospitalization and surgery. METHODS:Clinical data were collected for CD subjects including ...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1093/ibd/izz258

    authors: Sofia MA,Lipowska AM,Zmeter N,Perez E,Kavitt R,Rubin DT

    更新日期:2020-07-17 00:00:00

  • Early Surgery Versus Biologic Therapy in Limited Nonstricturing Ileocecal Crohn's Disease-A Decision-making Analysis.

    abstract:BACKGROUND:Surgery is the preferred option for patients with symptomatic localized fibrostenotic ileocecal Crohn's disease (CD) but not for those with predominantly active inflammation without obstruction. The benefit of early surgery in patients with a limited nonstricturing ileocecal CD over biologic treatment is sti...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1093/ibd/izz282

    authors: Broide E,Eindor-Abarbanel A,Naftali T,Shirin H,Shalem T,Richter V,Matalon S,Leshno M

    更新日期:2020-10-23 00:00:00

  • Higher Infliximab Levels Are Not Associated With an Increase in Adverse Events in Inflammatory Bowel Disease.

    abstract:Background:Patients requiring optimization of therapy for suboptimal response and/or targeting more robust outcomes may eventually reach high serum levels. Data evaluating the relationship between infliximab concentration and toxicity are limited. The aim of this study was to evaluate the frequency of adverse events (A...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1093/ibd/izy066

    authors: Greener T,Kabakchiev B,Steinhart AH,Silverberg MS

    更新日期:2018-07-12 00:00:00